Free Trial

Crinetics Pharmaceuticals (CRNX) Competitors

Crinetics Pharmaceuticals logo
$30.38 -0.04 (-0.12%)
As of 01:40 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CRNX vs. QGEN, VTRS, ASND, VRNA, BBIO, BPMC, ROIV, LEGN, ELAN, and RGC

Should you be buying Crinetics Pharmaceuticals stock or one of its competitors? The main competitors of Crinetics Pharmaceuticals include QIAGEN (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Legend Biotech (LEGN), Elanco Animal Health (ELAN), and Regencell Bioscience (RGC). These companies are all part of the "pharmaceutical products" industry.

Crinetics Pharmaceuticals vs. Its Competitors

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Qiagen has a net margin of 4.68% compared to Crinetics Pharmaceuticals' net margin of 0.00%. Qiagen's return on equity of 14.61% beat Crinetics Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Crinetics PharmaceuticalsN/A -30.95% -28.12%
Qiagen 4.68%14.61%8.80%

In the previous week, Crinetics Pharmaceuticals had 2 more articles in the media than Qiagen. MarketBeat recorded 8 mentions for Crinetics Pharmaceuticals and 6 mentions for Qiagen. Crinetics Pharmaceuticals' average media sentiment score of 1.48 beat Qiagen's score of 1.21 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Crinetics Pharmaceuticals
6 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Qiagen
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Crinetics Pharmaceuticals currently has a consensus target price of $69.50, suggesting a potential upside of 128.81%. Qiagen has a consensus target price of $49.40, suggesting a potential downside of 4.22%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Crinetics Pharmaceuticals is more favorable than Qiagen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Crinetics Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.80
Qiagen
0 Sell rating(s)
7 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.30

Crinetics Pharmaceuticals has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.

Qiagen has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crinetics Pharmaceuticals$1.04M2,734.63-$298.41M-$3.82-7.95
Qiagen$1.98B5.80$83.59M$0.40128.94

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 4.6% of Crinetics Pharmaceuticals shares are owned by company insiders. Comparatively, 9.0% of Qiagen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Qiagen beats Crinetics Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Crinetics Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRNX vs. The Competition

MetricCrinetics PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.84B$2.76B$5.70B$9.52B
Dividend YieldN/A1.78%4.60%3.99%
P/E Ratio-7.949.0628.0020.01
Price / Sales2,734.63738.63457.41102.39
Price / CashN/A166.2336.5558.97
Price / Book2.135.158.595.87
Net Income-$298.41M$30.99M$3.24B$258.50M
7 Day Performance-2.36%7.15%3.71%1.95%
1 Month Performance-0.12%15.55%10.26%12.31%
1 Year Performance-43.05%-1.12%34.07%19.02%

Crinetics Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRNX
Crinetics Pharmaceuticals
3.6781 of 5 stars
$30.38
-0.1%
$69.50
+128.8%
-43.1%$2.84B$1.04M-7.94210Positive News
QGEN
QIAGEN
3.7063 of 5 stars
$48.06
-0.6%
$49.40
+2.8%
+25.6%$10.75B$1.98B20.925,765Positive News
Analyst Revision
VTRS
Viatris
2.3592 of 5 stars
$8.90
+0.2%
$10.40
+16.9%
-20.1%$10.42B$14.74B3.5832,000
ASND
Ascendis Pharma A/S
3.4985 of 5 stars
$168.02
-1.1%
$223.07
+32.8%
+25.6%$10.39B$393.54M0.001,017Analyst Revision
VRNA
Verona Pharma PLC American Depositary Share
2.6872 of 5 stars
$104.90
flat
$109.00
+3.9%
+398.3%$8.93B$42.28M0.0030Positive News
BBIO
BridgeBio Pharma
4.6151 of 5 stars
$45.90
-1.3%
$61.50
+34.0%
+73.2%$8.83B$221.90M0.00400
BPMC
Blueprint Medicines
0.972 of 5 stars
$129.46
flat
$128.25
-0.9%
N/A$8.36B$562.12M-52.41640Upcoming Earnings
ROIV
Roivant Sciences
2.6491 of 5 stars
$11.48
+0.3%
$16.50
+43.7%
+5.9%$7.78B$29.05M0.00860News Coverage
Positive News
Insider Trade
LEGN
Legend Biotech
3.6854 of 5 stars
$42.23
+1.5%
$73.33
+73.7%
-25.9%$7.64B$627.24M0.002,609Positive News
ELAN
Elanco Animal Health
3.3886 of 5 stars
$14.67
-0.8%
$16.00
+9.1%
+12.7%$7.34B$4.44B15.729,000Analyst Forecast
RGC
Regencell Bioscience
0.3073 of 5 stars
$14.40
-0.7%
N/AN/A$7.17BN/A0.0010Gap Down

Related Companies and Tools


This page (NASDAQ:CRNX) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners